Activation of the STING pathway controls tumor growth in mouse models of melanoma and breast cancer, mediating systemic immunity by enhancing the efficacy of anti-PD-1/CTLA 4 therapy [148] or in combination with OX40 receptor and PD-L 1 blockade [149]. This evidence concerns the gene STING1 and neoplasm.